Dizal's first-in-class LYN/BTK dual inhibitor DZD8586 will be featured in oral and poster presentations for chronic lymphocytic leukemia and diffuse large B-cell lymphoma at ASCO 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.